AZ ORIN1001-002 D4325C00001: Phase 1b Double-Blind, Placebo-Controlled, Ascending Dose Trial: ORIN1001 in Subjects with Idiopathic Pulmonary Fibrosis

Administered By

Awarded By

Contributors

Start/End

  • April 8, 2022 - March 31, 2027